First published · Last updated
MA07.09 Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC
A journal article reporting a three-year survival update and biomarker analysis for neoadjuvant chemoimmunotherapy in potentially resectable Stage IIIA/IIIB non-small cell lung cancer. The content is published as a journal article by Elsevier BV on 2025-10-01.
Categories: public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 5/10
- Geographic reach
- 2/10
- Global importance
- 3/10
- Impact magnitude
- 4/10
- Positivity
- 5/10
- Urgency
- 2/10
Why it matters
The article provides multi-year survival and biomarker data relevant to treatment of Stage IIIA/IIIB NSCLC.

